BiotechTube
Home/Pipeline/Ciltacabtagene autoleucel (Carvykti)

Ciltacabtagene autoleucel (Carvykti)

Relapsed/Refractory Multiple Myeloma

Approved / Phase 3ActiveMultiple (e.g., NCT04181827, NCT04923893)

Key Facts

Indication
Relapsed/Refractory Multiple Myeloma
Phase
Approved / Phase 3
Status
Active
Company
Genscript Biotech

About Genscript Biotech

Founded in 2002, GenScript Biotech has evolved from a gene synthesis pioneer into a $24+ billion market cap global platform, serving over 200,000 clients worldwide. Its mission is to make biology easier and accelerate the transition from discovery to therapy. The company's strategy leverages its dominant Life Science Services segment as a powerful funnel to drive growth in its high-value Biologics CDMO and Cell Therapy businesses, creating a unique, synergistic ecosystem.

View full company profile

Therapeutic Areas

OncologyImmunology

Other Relapsed/Refractory Multiple Myeloma Drugs

DrugCompanyPhase
Aplidin (plitidepsin)PharmaMarApproved (Conditional - AU)
TECVAYLI + DARZALEX FASPROjohnson-and-johnson-innovative-medicineApproved
LinvoseltamabRegeneronPhase 3
Blenrep (belantamab mafodotin)GSKPhase III
CAR T-Cell Therapy ProgramDr. Reddy's LaboratoriesDevelopment
HDP-101Heidelberg PharmaPhase I/IIa
inobrodib + Pd (InoPd)CellCentricPhase 1/2
CT053CARsgen TherapeuticsPhase Ib/II
CT059CARsgen TherapeuticsPhase I
P-BCMA-ALLO1Poseida TherapeuticsPhase 1
P-BCMA-101Poseida TherapeuticsPhase 1/2
ABBV-383AbbViePhase 1